At a glance
- Originator Carlbiotech
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 11 Apr 1996 Discontinued-II for Glaucoma in Germany (Ophthalmic)
- 11 Apr 1996 Discontinued-II for Glaucoma in USA (Ophthalmic)
- 11 Apr 1996 Discontinued-II for Glaucoma in Denmark (Ophthalmic)